Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupropion for Stroke Recovery and Post-stroke Depression Prevention (ChiCTR2500105746)
ChiCTR2500105746Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in brain infarction and major depressive disorder (MDD) comparing Test group: bupropion + conventional treatment with Placebo control group: placebo + conventional treatment (2 arms). Primary endpoint: Proportion of subjects with mRS score 0–3 at day 90. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
bupropion
03
Conditions
brain infarctionmajor depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2500105746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105746.